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Background: In this study, we sequenced and phylogenetic analyses of the VP2 genes from twelve canine
parvovirus (CPV) strains obtained from eleven domestic dogs and a giant panda (Ailuropoda melanoleuca) in China.
A novel canine parvovirus (CPV) was detected from the giant panda in China.
Results: Nucleotide and phylogenetic analysis of the capsid protein VP2 gene classified the CPV as a new CPV-2a type.
Substitution of Gln for Arg at the conserved 370 residue in CPV presents an unusual variation in the new CPV-2a amino
acid sequence of the giant panda and is further evidence for the continuing evolution of the virus.
Conclusions: These findings extend the knowledge on CPV molecular epidemiology of particular relevance to
wild carnivores.
Keywords: Canine parvovirus, VP2 gene, Point mutation, Phylogenetic analysis, Giant pandaBackground
Canine parvovirus type 2 (CPV-2) is an important patho-
gen in domestic dogs and several wild carnivore species. It
was first identified in USA in 1978 and was found later to
have spread worldwide in domestic and wild canine popu-
lations. CPV-2 is a small non-enveloped, singe-stranded
DNA virus (5.2 Kb) which is a member of the genus
Parvovirus of the family Parvoviridae. The CPV genome is
composed of two major ORFs, one encoding the two non-
structural proteins [NS1 and NS2] and the other encoding
the two capsid proteins [VP1 and VP2] [1]. There is also a
third protein, VP3 which is produced by proteolytic pro-
cessing of VP2.
CPV-2 is antigenically and genetically related to feline
panleukopenia virus (FPLV). However, FPV infects cats,
mink and raccoons, but not dogs, whereas CPV-2 infects
dogs and other Canidae, but not cats. A few amino acid
differences between CPV and FPV determine the specifi-
city of these viruses [2]. After the CPV-2 initial appearance* Correspondence: yanqigui@126.com
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reproduction in any medium, provided the or(during 1978–1981), two new antigenic variants, named
CPV-2a and CPV-2b, were characterized [3-5]. The anti-
genic types CPV-2a and CPV-2b differ from the original
CPV-2 in at least five or six amino acids/residues of the
VP2 capsid protein (genomic positions 3045, 3685, 3699,
4062 and 4449) [6,7]. Canine parvovirus type 2a/2b having
mutation at 297 residue (Ser→Ala) is designated as new
CPV-2a/2b [8,9], residue 297 is located in a minor anti-
genic site close to epitope B and substitutions at this pos-
ition may be responsible for changes in antigenicity of
CPV variants [10]. Another antigenic variant having an
amino acid substitution 426-Asp→Glu was reported for
the first time in Italy [11] and had been reported from
other countries [1,12-17], and this variant is currently
named as CPV-2c.
It has been reported that canine parvovirus (CPV)
have been implicated in disease and mortality in giant
pandas [18-21], which is an endangered species native to
the China. The giant pandas with CPV infection showed
diarrhea, vomiting and water-like feces [18]. Giant panda
parvovirus VP2 gene described here identifies yet an-
other variant of the virus. It demonstrates the continued
adaptation of the virus to an everexpanding host range. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ding emergent disease theats is important in enabling
effective conservation measures for endangered species.
Results
Out of 36 faecal samples of giant pandas and 97 canine
rectal swabs screened by PCR assay using Hfor/Hrev
primers, 1 giant panda and 62 dog samples yielded a
specific amplicon of 611 bp, respectively.
The amplified PCR products of 11 randomly selected
canine samples and one giant panda sample were
subjected for sequencing using primer pair Hfor/Hrev.
Primer pair Hfor/Hrev [11] encompasses informative
amino acid residues which are of significance in charac-
terizing the CPV types. All the CPV samples under study
were found to be new CPV-2a (CPV-2a with nucleotide
variation T→G at position 3675 or CPV-2a with amino
acid variation 297-Ser→Ala). In comparison to prototype
new-CPV-2a (AY742953), the samples under this study
had amino acid residue variations at Tyr324Ile caused
by mutation TAT →ATT at nt 3756–3758 of the VP2
gene. It was a unique mutation within the VP2 of Chinese
and Korean strains of “new CPV-2a”. Critical positions of
the CPV VP2 gene products of samples sequenced in this
study are summarized in Table 1.
In addition to the nucleotide variations at positions
3675 and 3756, three additional mutations were observed
in the canine parvovirus sequences under study. One was
at nucleotide position 3584 where a mutation (U→A)
resulting in the codon change from UUC→UAC, with
amino acid variation 267-Phe→Tyr. All the sequences
under this study except B03, B06 and B11 showed this
variation. The second one was at nucleotide position
4110, where variation A→G was observed and which
changed the codon from ACG→GCG, with amino acid
variation 442-Thr→Ala. This variation (A→G) atTable 1 CPV strains from China, origin from which they were
Serial no Strain Host Foster mode
1 A10 Dog Captive
2 A11 Dog Captive
3 A12 Dog Captive
4 B01 Dog Captive
5 B02 Dog Captive
6 B03 Dog Captive
7 B04 Dog Captive
8 B05 Dog Captive
9 B06 Dog Captive
10 B07 Dog Captive
11 B11 Giant panda Captive
12 B12 Dog Captivenucleotide position 4110 was observed in strains A10,
A11, A12, B01, B02, B05, B07 and B12 in this study (the
dog samples). The last mutation was at nucleotide pos-
ition 3894 where a mutation (A→G) resulting in the
codon change from CAA→CGA, with amino acid vari-
ation 370-Gln→Arg. This variation only was revealed
in strain B11 (the giant panda sample).
To analyse the phylogenetic relationships of the China
isolates with other CPV strains isolated in various parts
of the world, we constructed a maximum likelihood
phylogenetic tree. The panda field isolate B11 was found
to be phylogenetically closely related to new CPV-2a
strains of Jilin strain CNJL0804. B06 and B03 are the
closest of Chinese dog sequences examined in this study.
Rest of the other sequences had distinct lineage but
shared molecular relationship with new CPV-2a refe-
rence strains (Figure 1).
Discussion
New CPV-2a/2b appear to have replaced the prototype
CPV-2a/2b strains and become the predominant types
in many countries [22-26]. In China, the prevalent anti-
genic type in canine populations is type 2a, our results
seem to confirm these data [27]. The dog and giant
panda samples were all new CPV-2a, but it is impossible
to conclude that new CPV-2a is predominant strain in
the China dog or giant panda population because our
data are limited to an exiguous number of samples and
we do not have data regarding CPV-2 dog strains from
the area where the giant panda samples were collected.
All the CPV clinical samples under study were found
to be new CPV-2a (Figure 1). Similar substitution 297-
Ser→Ala in CPV-2a strain were reported in VP2 gene of
CPV from worldwide [2,22,28-30]. This study detected
one site mutation among the CPV-2a isolates in China:
Tyr→Ile at position 324, This mutation was alsoisolated and their GenBank accession numbers
Vaccinated Origins GenBank no.
Yes Rectal swabs JX624761
Yes Rectal swabs JX624762
Yes Rectal swabs JX624763
Yes Rectal swabs JX624764
Yes Rectal swabs JX624765
Yes Rectal swabs JX624766
Yes Rectal swabs JX624767
Yes Rectal swabs JX624768
Yes Rectal swabs JX624769
Yes Rectal swabs JX624770
Yes Faecal JX624771
Yes Rectal swabs JX624772
Figure 1 (See legend on next page.)
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Figure 1 Maximum likelihood tree (Mega-5.1 beta version) constructed using canine parvovirus sequences under study and the
reference sequences. M38246 (FPV, USA), M38245 (CPV-2, USA), M24003 (CPV-2a, USA), M74849 (CPV-2b, USA), AY742953 (New CPV-2a, USA),
AY742955 (New CPV-2b, USA), DQ182620 (New CPV-2a, India), DQ182623 (New CPV-2b, India), D78585 (New CPV-2a, Japan), AB054220 (New CPV-
2b, Japan), AY742938 (New CPV-2a, Germany), AY742934 (New CPV-2b, Germany), AY742942 (CPV-2c, Germany), AF306447 (New CPV-2a, Italy),
AF306444 (CPV-2b, Italy), FJ222821 (CPV-2c, Italy), AB054222 (CPV-2c(a), Japan), AB054215 (New CPV-2a, Vietnam), AB054224 (CPV-2c(a), Vietnam),
U72698 (New CPV-2a, Taiwan), U72696 (New CPV-2b, Taiwan), FJ197835 (New CPV-2a, South Korea), EF599097 (New CPV-2b, South Korea),
DQ903936 (New CPV-2a, China), FJ435343 (New CPV-2a, China), FJ435342 (CPV-2, China), FJ435344 (CPV-2, China), FJ435345 (New CPV-2a, China),
FJ435346 (New CPV-2a, China), FJ435347 (New CPV-2a, China), FJ435348 (CPV-2, China), EF599097 (New CPV-2b,South Korea), AB054215 (New
CPV-2a, Japan), EF028071 (New CPV-2b, China), GQ169552 (CPV-2, China), Triangle (▲) indicates the 12 Chinese wild-type CPV strains analyzed in
this study. Green and red were used for dog and giant panda strains, respectively.
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residue 324 is subject to strong positive selection in all
parvoviruses of carnivores [32].
The natural adaptation of a virus to a new host is a
very rare event, suggesting that there are high barriers
that prevent viruses from gaining the ability to infect
and spread naturally in hosts to which they are not
adapted. In this study, the novel point mutation virus is
most likely not a panda-adapted virus spreading among
pandas, but more likely a spill-over from dogs. Because
host adaptation involved complex interactions among
both surface-exposed and buried capsid mutations that
together altered cell infection and immune escape prop-
erties of the viruses [33]. In this study, the virus VP2
gene coding change at nt 3894 (VP2 residue 370,
Gln→Arg) was interesting because it has not been
detected previously in any other strains. We speculated
that the mutation has two aspect functions. On the one
hand, residue 370 was close to residues 375 and 377, it
has indicated that residues 375 and 377 are associated
with the ability of CPV to hemagglutinate or alter pH
dependence of hemagglutination [34], On the other
hand, residue 370 was adjacent to residue 379 and 384,
while the 379 and 384 residue affects canine transferrin
receptor (TfR) binding to determined the canine host
range [35]. So, we made the inferences that R370 might
be involved in a required conformational change, or it
might mediate an effect on receptor binding through the
neighboring residues, and is likely to have had an effect
on the parvovirus host range. This observation suggests
that the glutamine to arginine mutation may also affect
host DNA±protein interaction. As is the case for wild
animal, this mutation is not selected for the population,
but may have arisen independently from various
backgrounds.
As the phylogenetic tree shows, most of the viruses
isolated in China formed a large cluster, while some
strains clustered together with viruses from regions out-
side China. Most of the CPVs isolated in China formed a
specific cluster and certain mutations detected in Chin-
ese CPVs probably arose during the process of local
adaptation, as indicated by previous surveys [36].Considering that the CPV-2 vaccine appears to provide
a comparatively lower and shorter immunity against
heterologous CPVs, there is evidences to suggest that
complete immunity may not be provided to dogs even if
CPV-2 vaccines are used [37-39]. In many countries,
such as Europe, CPV-2a has been overtaken by CPV-2b
or CPV-2c, some researches have been to evaluate anti-
genic relationships among the original canine parvovirus
type 2 (CPV-2) and the variants CPV-2a, -2b, and -2c,
cross-antigenic evaluation revealed clear differences
among the CPV variants [40]. Nevertheless, our study
showed that the giant panda and dogs are all new CPV-
2a type, while the vaccines available for giant pandas and
dogs are CPV-2 type vaccine in China (Nobivac®, Hol-
land) [41]. The effectiveness of CPV-2 vaccine against
CPV-2a type has not been evaluated in China.
In sum, wildlife in captive facilities in China is gener-
ally not reliably or safely vaccinated. Strain difference be-
tween field virus and vaccine candidate virus could be
one of the important attributable reasons for some
immunization failure. Infectious diseases pose a signifi-
cant risk to these animals, of which many are endan-
gered species, the mechanisms of the virus into the giant
panda population and the adaptation (mutation) of the




The animal from which specimens were collected, was
handled in accordance with animal protection law of the
People’s Republic of China (a draft of an animal protec-
tion law in China released on September 18, 2009). This
study was approved by the National Institute of Animal
Health Animal Care and Use Committee at Sichuan
Agricultural University (approval number 2010–020).
Clinical samples
A total of 36 faecal samples of giant pandas and 97 rec-
tal swabs were collected from dogs suspected to be
Table 2 Alignment of the deduced amino acid sequences of partial VP2 gene
Aa residue 267 297 300 305 324 370 375 426 442
Nt position 3585-3588 3675-3577 3684-3686 3699-3701 3756-3769 3894-3897 3909-3912 4064-4067 4112-4115
M38245(CPV-2) F S A D Y Q N N T
M24003(CPV-2a) F S G Y Y Q D N T
M74849(CPV-2b) F S G Y Y Q D D T
FJ222821(CPV-2c) F A G Y Y Q D E T
AB054215(FPV) F A G Y Y Q D N T
AY742953(New-CPV-2a) F A G Y Y Q D N T
AY742955(New-CPV-2b) F A G Y Y Q D D T
JX624761(A10) Y A G Y I Q D N A
JX624762(A11) Y A G Y I Q D N A
JX624763(A12) Y A G Y I Q D N A
JX624764(B01) Y A G Y I Q D N A
JX624765 (B02) Y A G Y I Q D N A
JX624766(B03) F A G Y I Q D N T
JX624767(B04) Y A G Y I Q D N T
JX624768(B05) Y A G Y I Q D N A
JX624769(B06) F A G Y I Q D N T
JX624770(B07) Y A G Y I Q D N A
JX624771(B11) F A G Y I R D N T
JX624772(B12) Y A G Y I Q D N A
Sequence of one of the representative canine parvovirus field isolate GU139553 (New CPV-2a) is shown aligned with the reference strains M38246 (FPV), M38245
(CPV-2), M24003 (CPV-2a), M74849 (CPV-2b), AY742953 (New CPV-2a), AY742955 (New CPV-2b) and FJ222821 (CPV-2c) obtained from the Genbank.
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Detailed information on the origin and the accession
numbers of the CPV-positive samples is shown in
Table 2. All activities followed the legal requirements
and institutional guidelines set out by the government of
P.R. China. The samples were collected in China dur-
ing a period of 7 months from November 2011 to May
2012. The collected samples were emulsified in 2 ml
of 0.1 M PBS of pH 7.4 and centrifuged at 6000 g for
15 min at 4°C. The supernatant was collected and used
for PCR amplification.
Template DNA preparation
Hundred microlitres of the processed supernatant was
used for template DNA preparation by boiling at 96°C
for 10 min and chilling immediately in crushed ice
[42,43]. The supernatants were diluted 1:10 in distilled
water to reduce residual inhibitors of DNA polymerase
activity [12].
Primer pair and PCR amplification
PCR amplification was performed using KOD-Plus-Ver.2
(TOYOBO, Japan) and primer pair Hfor (5′-CAGGTG
ATGAATTTGCTACA-3′)/Hrev (5′-CATTTGGATA -
AACTGGTGGT-3′) that amplifies 611 bp fragment of
the gene encoding capsid protein [11]. PCR amplificationwas consisted of 30 cycles of denaturation (95°C 45 s),
annealing(51°C 45 s), extension (72°C 45 s) and final ex-
tension (72°C 10 min) and the products were analyzed by
electrophoresis using 1.5% agarose gel in Tris acetate
EDTA (TAE) buffer (1×).Sequencing and phylogenetic analysis
PCR products of the correct size (611 bp in length) were
amplified and cloned using TArget Clone-Plus-(TOYOBO,
Japan),then custom sequenced with primer pair Hfor/
Hrev. The sequences were aligned with sequences of
prototype CPV strains (M38246-FPV; M38245-CPV-2;
M24003-CPV-2a; M74849-CPV-2b; AY742953- New
CPV-2a; AY742955-New CPV-2b; FJ222821-CPV-2c)
using Clustal W (http://www.clustal.org). The sequences
were analyzed with respect to the prototype CPV-2 strain
for the nucleotide variation of VP2 gene at positions 3675,
3684, 3699, 3756, 3909 and 4062 with the corresponding
amino acid residues at 297, 300, 305, 324, 375 and 426,
respectively.
For the phylogenetic analysis, 35 canine parvovirus se-
quences from various parts of the world were retrieved
from the GenBank and used. The sequences were
aligned using Clustal W. Maximum likelihood tree was
drawn using the MEGA 5.0 Software [44].
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